ALNY vs. KYMR: Alnylam Pharmaceuticals vs. Kymera Therapeutics Stock Comparison

Company Profile

Alnylam Pharmaceuticals (ALNY) and Kymera Therapeutics (KYMR) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Alnylam Pharmaceuticals (ALNY) has more than two decades of public-market history since June 1, 2004, whereas Kymera Therapeutics (KYMR) listed on August 21, 2020 and has a much shorter record to draw on.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Kymera Therapeutics (KYMR) has an aggressive beta of 2.00, indicating higher sensitivity to broad-market moves, while Alnylam Pharmaceuticals (ALNY) is defensive at 0.45 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Kymera Therapeutics (KYMR) reports a negative ROE of -27.29%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Alnylam Pharmaceuticals (ALNY) reports 138.07%, ranking against industry peers normally.

Alnylam Pharmaceuticals (ALNY) at 52.85% converts revenue to bottom-line profit above its industry’s benchmark range, while Kymera Therapeutics (KYMR) at 0.00% keeps roughly the typical share for its industry.

Kymera Therapeutics (KYMR) reports a negative operating margin of -396.04%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Alnylam Pharmaceuticals (ALNY) reports 23.72%, ranking against industry peers normally.

Profitability Metrics

Growth

Alnylam Pharmaceuticals (ALNY) at 65.19% sits in the top revenue growth quartile, while Kymera Therapeutics (KYMR) at -16.70% is in the bottom quartile, showing a clear gap in revenue momentum.

Neither Alnylam Pharmaceuticals (ALNY) nor Kymera Therapeutics (KYMR) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Financial Strength

Both Alnylam Pharmaceuticals (ALNY) at 2.48 and Kymera Therapeutics (KYMR) at 11.13 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

Kymera Therapeutics (KYMR) at 0.05 carries an industry-typical debt-to-equity mix, while Alnylam Pharmaceuticals (ALNY) at 0.83 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Neither Alnylam Pharmaceuticals (ALNY) nor Kymera Therapeutics (KYMR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Alnylam Pharmaceuticals (ALNY) nor Kymera Therapeutics (KYMR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Alnylam Pharmaceuticals (ALNY) trades at 7.88 times trailing earnings, ranked against its peers, while Kymera Therapeutics (KYMR) has no P/E ratio this period.

Alnylam Pharmaceuticals (ALNY) at 4.17 prices around its industry’s typical P/S ratio, while Kymera Therapeutics (KYMR) at 110.00 clears its benchmark range — KYMR looks notably rich on sales.

Alnylam Pharmaceuticals (ALNY) at 5.79 is valued about in line with its industry on P/B ratio, while Kymera Therapeutics (KYMR) at 6.96 carries an above-peer premium to book — KYMR is pricier on assets.

Valuation Metrics